v3.20.2
STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (61,083) $ (24,693)
Reconciliation of net loss to net cash used in operating activities    
Depreciation and amortization 143 218
Stock-based compensation expense 8,000 2,488
Changes in operating assets and liabilities:    
Prepaid expenses, other assets and right of use assets (846) (618)
Accounts payable, accrued expenses, lease liabilities and other liabilities 7,708 3,423
Net cash used in operating activities (46,078) (19,182)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of equipment and leasehold improvements (46) (868)
Net cash used in investing activities (46) (868)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock, net of issuance costs 255,819 17,736
Purchase and cancellation of shares from BioXcel Corporation (9,024)  
Exercise of options 331 1
Net cash provided by financing activities 247,126 17,737
Net increase (decrease) in cash and cash equivalents 201,002 (2,313)
Cash and cash equivalents, beginning of the period 32,426 42,565
Cash and cash equivalents, end of the period 233,428 40,252
Supplemental cash flow information:    
Interest paid 23 47
Operating lease right of use asset and liability (non-cash adoption balances)   $ 1,308
Operating ROU lease assets obtained in exchange for operating lease liabilities $ 606  

Source